Search - tctmd.com

Displaying 361 - 380 of 3210

Sort: Relevancy | Date

Presentation NY Valves 2025

Impact of Myosin Inhibitors on Cardiac Remodeling in HCM: Different from Septal Reduction Therapies?

Presenter: Shepard D. Weiner

June 25, 2025

Presentation NY Valves 2025

A Contemporary View on Pathophysiology and Clinical Significance of LVOT in HCM

Presenter: Anjali Owens

June 25, 2025

Presentation NY Valves 2025

SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results

Presenter: Pradeep K. Yadav

June 25, 2025

Presentation NY Valves 2025

Key Take-Aways

Presenter: Rishi Puri

June 25, 2025

Presentation NY Valves 2025

Heart Team Discussion: Lifetime Management Considerations

Presenter: Sachin S. Goel

June 25, 2025

Presentation NY Valves 2025

Heart Team Discussion: Importance of Preserving Coronary Access after TAVI

Presenter: Laura Flannery

June 25, 2025

Presentation NY Valves 2025

Navitor Vision Valve Case Presentation

Presenter: Mark J. Ricciardi

June 25, 2025

Presentation NY Valves 2025

Heart Team Discussion: Optimal Implantation Technique

Presenter: Saurabh Sanon

June 25, 2025

Presentation NY Valves 2025

Heart Team Discussion: Importance of PPM

Presenter: Rishi Puri

June 25, 2025

Presentation NY Valves 2025

Case background

Presenter: Mark J. Ricciardi

June 25, 2025

Presentation NY Valves 2025

Welcome and Learning Objectives

Presenter: Rishi Puri

June 25, 2025

Presentation NY Valves 2025

SESAME for the Treatment of Subaortic Membrane: First-in-Human Series

Presenter: Yasemin Ciftcikal

June 25, 2025

Presentation NY Valves 2025

Advantages of Splitting Bicuspid Aortic Valve Leaflets Prior to TAVR: A New Paradigm for Leaflet Modification in BAV?

Presenter: Hasan Jilaihawi

June 25, 2025

Presentation NY Valves 2025

BONAPART: A Novel Mechanical Leaflet Splitting Device

Presenter: Eberhard Grube

June 25, 2025

Presentation NY Valves 2025

The Evolution of Leaflet Modification Technologies: Emerging Techniques (e.g. UNICORN, BATMAN, etc), Technologies and Future Applications

Presenter: Jaffar M. Khan

June 25, 2025

Presentation NY Valves 2025

M-TEER for Atrial and Ventricular SMR: Insights from the REPAIR Study

Presenter: Philipp von Stein

June 25, 2025

Presentation NY Valves 2025

Clipping Strategies and Outcomes in Atrial SMR Patients Treated with the MitraClip System

Presenter: Mark J. Ricciardi

June 25, 2025

Presentation NY Valves 2025

Effect of TTVR on Preference-Weighted Health Status: A Patient-Centered Sub-Study of the TRISCEND II Pivotal Trial

Presenter: Suzanne V. Arnold

June 25, 2025

Presentation NY Valves 2025

Early Outcomes of Real-World TTVR (Evoque)

Presenter: Fabien Praz

June 25, 2025

Presentation NY Valves 2025

Clinical and Economic Outcomes by Stage of Cardiac Damage and Clinical Presentation at Aortic Valve Replacemen

Presenter: Philippe Genereux

June 25, 2025

Advertisement

Impact of Myosin Inhibitors on Cardiac Remodeling in HCM: Different from Septal Reduction Therapies?

A Contemporary View on Pathophysiology and Clinical Significance of LVOT in HCM

SIEGEL TAVR: FIH 1 year & US Early Feasibility 30 Day Results

Key Take-Aways

Heart Team Discussion: Lifetime Management Considerations

Heart Team Discussion: Importance of Preserving Coronary Access after TAVI

Navitor Vision Valve Case Presentation

Heart Team Discussion: Optimal Implantation Technique

Heart Team Discussion: Importance of PPM

Case background

Welcome and Learning Objectives

SESAME for the Treatment of Subaortic Membrane: First-in-Human Series

Advantages of Splitting Bicuspid Aortic Valve Leaflets Prior to TAVR: A New Paradigm for Leaflet Modification in BAV?

BONAPART: A Novel Mechanical Leaflet Splitting Device

The Evolution of Leaflet Modification Technologies: Emerging Techniques (e.g. UNICORN, BATMAN, etc), Technologies and Future Applications

M-TEER for Atrial and Ventricular SMR: Insights from the REPAIR Study

Clipping Strategies and Outcomes in Atrial SMR Patients Treated with the MitraClip System

Effect of TTVR on Preference-Weighted Health Status: A Patient-Centered Sub-Study of the TRISCEND II Pivotal Trial

Early Outcomes of Real-World TTVR (Evoque)

Clinical and Economic Outcomes by Stage of Cardiac Damage and Clinical Presentation at Aortic Valve Replacemen

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content